What's happened
A comprehensive review has found that drugs targeting amyloid plaques in the brain do not significantly improve cognitive function or slow Alzheimer’s disease progression. The review, analyzing over 20,000 patients, indicates these treatments cause side effects and offer minimal clinical benefit, prompting calls for new research directions.
What's behind the headline?
The review’s findings challenge the narrative that anti-amyloid drugs are effective treatments for Alzheimer’s. Despite their ability to remove amyloid plaques, the drugs have not demonstrated meaningful improvements in cognition or disease severity. This underscores a critical flaw in current drug development strategies, which focus heavily on amyloid clearance. The pooling of data from both failed and successful drugs has been criticized, but it reveals that the clinical benefits are consistently small. This will likely shift research efforts toward exploring alternative biological targets. The approval of lecanemab and donanemab, despite their limited benefits, reflects regulatory and commercial pressures that may now be reconsidered. The findings will increase pressure on regulators and healthcare providers to re-evaluate treatment protocols and funding, emphasizing the need for innovative approaches that address the complex pathology of Alzheimer’s disease.
What the papers say
The Guardian reports that the extensive review has found the effects of anti-amyloid drugs to be 'trivial' and highlights the side effects such as brain swelling and bleeding. Ian Sample notes that the drugs have not produced meaningful improvements in cognition over 18 months, despite regulatory approvals. The Japan Times emphasizes that the drugs do not slow disease progression and that many trials have failed, with some experts criticizing the pooling of results from different drugs. Meanwhile, the New York Times discusses the controversy surrounding the review’s methodology, with some experts arguing that it oversimplifies the potential benefits of recent drugs like lecanemab and Kisunla. The Independent points out that the review’s conclusions have prompted re-evaluation by health authorities and ongoing debate about the future of Alzheimer’s treatment development.
How we got here
Recent years have seen the approval of anti-amyloid drugs like lecanemab and donanemab, based on their ability to clear amyloid plaques from the brain. These drugs have been hailed as breakthroughs, but their actual impact on disease progression remains controversial. The review consolidates data from multiple trials conducted over the past two decades, highlighting the limited efficacy of these treatments and raising questions about their long-term value.
Go deeper
More on these topics